ArticleBreast cancer research and treatment2026
Breast skin ulceration in de novo metastatic breast cancer: incidence, predictors, and patterns of occurrence.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to identify factors associated with breast skin ulceration (BSU) and to describe its timing and patterns of occurrence in de novo metastatic breast cancer (MBC).
methodsWe conducted a retrospective cohort study including women diagnosed with de novo MBC between 2008 and 2019 at Institut Curie. Clinical, pathological, and treatment-related data were extracted from the ESME database, a large, nationwide French real-world database dedicated to metastatic breast cancer. The primary endpoint was the presence or development of BSU. Secondary endpoints included progression-free survival (PFS) and overall survival (OS).
resultsAmong 669 patients with de novo MBC, 53 (7.9%) presented with or developed BSU. Ulceration was present at diagnosis in 50 cases (94%), whereas secondary BSU during follow-up was rare (n = 3). All secondary BSU occurred in non-operated inflammatory tumors (T4d), and no secondary BSU was observed in non-inflammatory disease. Larger tumor size, inflammatory presentation, and higher metastatic burden were associated with BSU. In unadjusted analyses, BSU was associated with shorter PFS and OS, but this association was no longer significant after multivariable adjustment.
conclusionsBreast skin ulceration in de novo MBC is an uncommon event that primarily reflects aggressive inflammatory tumor behavior rather than inadequate locoregional management. Secondary BSU is exceptionally rare and confined to inflammatory tumors. Systematic routine surgical intervention solely to prevent ulceration appears unjustified in non-inflammatory disease.
Indexed as
Identifiers
42584500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.